Dmitry Vinogradov
Citi launched its coverage of Structure Therapeutics with a Buy recommendation and a $60 per share target on Friday, citing potential partnership interest in the company’s oral drug pipeline led by obesity therapies.
The San Francisco, California-based biotech’s lead asset, aleniglipron, is currently
